Sunitinib in the treatment of advanced renal cell carcinoma

Arsenal of a modern chemotherapist exists on a wide choice of treatment of metastatic renal cell carcinoma – the discovery of immunodrugs – checkpoint inhibitors, new multikinase inhibitors and their combinations allow choosing the optimal treatment for patients of any risk group. However, the increase in the economic burden on a medical institution, which is observed every year with the emergence of more and more indications for antitumor therapy, is a limitation for the full implementation of modern immuno-targeted regimens. Therefore, it is necessary to consider the possibility of using more affordable drug options that are optimal in their antitumor response and are not significantly inferior to the newly introduced schemes. The article presents a brief overview of the mechanism of resistance of a renal cell tumor to drug exposure, describes the evolution of drug therapy for metastatic kidney cancer before the advent of sunitinib: attempts to use various cytotoxic agents, the development of immune-mediated cytokine therapy. The results of clinical trials of sunitinib in the treatment of renal cell carcinoma, comparative studies of RECORD-3 and COMPARZ, as well as private clinical cases of the use of sunitinib in real clinical practice are described. Clinical cases show the efficacy and safety of sunitinib in the presented patients – the time without progression was 30 and 26 months, and adverse events were controlled and consistent with ongoing clinical trials: patients had hematological toxicity in the form of neutropenia, anemia, arterial hypertension, dermatological toxicity in the form of discoloration hairline and palmar-plantar syndrome. All phenomena were successfully stopped, only in the case of neutropenia, the drug was postponed until the restoration of hematological parameters. It is noted that sunitinib occupies an important place in the treatment of metastatic kidney cancer at the present time.

1. Mickisch G.H. Chemoresistance of renal cell carcinoma: 1986–1994. World J Urol. 1994;12(4):214–223. https://doi.org/10.1007/BF00185677.

2. Fosså S.D., Droz J.P., Pavone-Macaluso M.M., Debruyne F.J., Vermeylen K., Sylvester R. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer. 1992;28(4–5):878–880. https://doi.org/10.1016/0959-8049(92)90139-s

3. Stadler W.M., Huo D., George C., Yang X., Ryan C.W., Karrison T. et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003;170(4):1141–1145. https://doi.org/10.1097/01.ju.0000086829.74971.4a.

4. Bennouna J., Delva R., Gomez F., Lesimple T., Geoffrois L., Linassier C. et al. A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology. 2003;64(1):25–27. https://doi.org/10.1159/000066518.

5. Oevermann K., Buer J., Hoffmann R., Franzke A., Schrader A., Patzelt T. et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Сancer. 2000;83(5):583–587. https://doi.org/10.1054/bjoc.2000.1340.

6. Dickerson E.C., Davenport M.S., Liu P.S. Spontaneous regression of primary renal cell carcinoma following image-guided percutaneous biopsy. Clin Imaging. 2015;39(3):520–524. https://doi.org/10.1016/j.clinimag.2014.08.002.

7. Makhov P., Joshi S., Ghatalia P., Kutikov A., Uzzo R.G., Kolenko V.M. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Сancer Тher. 2018;17(7):1355–1364. https://doi.org/10.1158/1535-7163.MCT-17-1299.

8. Doehn C., Kausch I., Melz S., Behm A., Jocham D. Cytokine and vaccine therapy of kidney cancer. Expert Rev Anticancer Тher. 2004;4(6):1097–1111. https://doi.org/10.1586/14737140.4.6.1097.

9. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Сancer Res. 2003;9(1):327–337. Available at: https://pubmed.ncbi.nlm.nih.gov/12538485.

10. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90. https://doi.org/10.1038/ng0594-85.

11. Menshikov K.V., Izmailov A.A., Sultanbaev A.V., Musin S.I., Chalov V.S., Menshikova I.A. et al. Metastatic renal cell carcinoma, the possibility of targeted therapy. Meditsinskiy Sovet. 2021;(20):138–144. (In Russ.) https://doi.org/10.21518/2079-701X-2021-20-138-144.

12. Jonasch E., Walker C.L., Rathmell W.K. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–261. https://doi.org/10.1038/s41581-020-00359-2.

13. Choueiri T.K., Kaelin W.G.Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26(10):1519–1530. https://doi.org/10.1038/s41591-020-1093-z.

14. Kalpinsky A.S., Alekseev B.Ya. The effectiveness of sunitinib in targeted therapy of metastatic kidney cancer. Onkourologiya. 2009;5(3):63–67. (In Russ.) Available at: https://oncourology.abvpress.ru/oncur/article/view/272.

15. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 2007;356(2):115–124. https://doi.org/10.1056/NEJMoa065044.

16. Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Engl J Med. 2013;369(8):722–731. https://doi.org/10.1056/NEJMoa1303989.

17. Knox J.J., Barrios C.H., Kim T.M., Cosgriff T., Srimuninnimit V., Pittman K. et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017;28(6):1339–1345. https://doi.org/10.1093/annonc/mdx075.

18. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. https://doi.org/10.1200/JCO.2008.21.4809.

19. Alekseev B.Ya., Shevchuk I.M. New lenvatinib and pembrolizumab combination for metastatic renal cell carcinoma in 1st line drug treatment: comparative effectiveness and safety. Onkourologiya. 2022;18(3):51–59. (In Russ.) https://doi.org/10.17650/1726-9776-2022-18-3-51-59.

20. Rini B.I., Plimack E.R., Stus V., Gafanov R., Hawkins R., Nosov D. et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Engl J Med. 2019;380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714.

21. Powles T., Plimack E.R., Soulières D., Waddell T., Stus V., Gafanov R. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573. https://doi.org/10.1016/S1470-2045(20)30436-8.

22. George D.J., Lee C.H., Heng D. New approaches to first-line treatment of advanced renal cell carcinoma. Ther Adv Med Oncol. 2021;13:17588359211034708. https://doi.org/10.1177/17588359211034708.

23. Motzer R.J., Tannir N.M., McDermott D.F., Arén Frontera O., Melichar B., Choueiri T.K. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New Engl J Med. 2018;378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126.

24. Menshikov K.V., Sultanbaev A.V., Musin Sh.I., Izmailov A.A., Menshikova I.A., Nasretdinov A.F. et al. Experience of using tyrosine kinase inhibitor kabozantinib in the Republic of Bashkortostan. Oncology Bulletin of the Volga Region. 2022;13(2):7–20. (In Russ.) Available at: http://oncovestnik.ru/archive/zhurnaly-za-2022-god/tom-13-nomer-2-2022-g/opyt-primeneniyatirozinkinaznogo-ingibitora-kabozantiniba-v-respublike-bashkortostan.